Ambros Therapeutics

Ambros Therapeutics is a clinical-stage biotechnology company focused on developing innovative and transformative therapies for high unmet medical needs. Ambros’ lead research program targets Complex Regional Pain Syndrome Type 1 (CRPS-1). The Phase III pivotal trial (CRPS-RISE) is planned to initiate recruitment in the first quarter of 2026, representing a potential first-of-its-kind approach for a disease with no FDA-approved treatment.